beta
Trial Radar AI
Clinical Trial NCT07492043 (BREVIA) for Breast Cancer, Ductal Carcinoma In Situ is not yet recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here.
One study matched filter criteria
Card View
Back to Search

Breast Tumour Size Measurement by Field Cycling Imaging (BREVIA) 12

Not yet recruiting
Clinical Trial NCT07492043 (BREVIA) is an observational study for Breast Cancer, Ductal Carcinoma In Situ and is currently not yet recruiting. Enrollment is planned to begin on 1 April 2026 and continue until the study accrues 12 participants. Led by University of Aberdeen, this study is expected to complete by 1 December 2026. The latest data from ClinicalTrials.gov was last updated on 25 March 2026.
Brief Summary
The goal of this study is to test if a new type of MRI scanner, called Field-Cycling Imaging (FCI), can accurately estimate tumour size in patients with a type of breast cancer called ductal carcinoma in situ (DCIS). The main question it aims to answer is:

Can FCI accurately estimate DCIS lesion size compared with histology results?

Participants will have a standard MRI scan and an FCI scan before undergoing surger...

Show More
Official Title

Breast Tumour Size Measurement by Field Cycling Imaging

Conditions
Breast CancerDuctal Carcinoma In Situ
Publications
Scientific articles and research papers published about this clinical trial:
Other Study IDs
  • BREVIA
  • 2-082-25
  • 25/NW/0355 (Other Identifier) (North West - Preston Research Ethics Committee)
NCT ID Number
NCT07492043
Start Date (Actual)
2026-04
Last Update Posted
2026-03-25
Completion Date (Estimated)
2026-12
Enrollment (Estimated)
12
Study Type
Observational
Status
Not yet recruiting
Keywords
Field-Cycling Imaging
FCI
DCIS
Breast Cancer
Arms / Interventions
Participant Group/ArmIntervention/Treatment
Breast Cancer
Participants with breast cancer of ductal carcinoma in-situ (DCIS) who are due to undergo surgical treatment.
Field-Cycling Imaging research scan
Baseline FCI scan
3T MRI research scan
Baseline MRI scan
Primary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Accuracy of DCIS lesion size estimation using FCI, validated against histopathological measurements (gold standard).
Extent of agreement between lesion size estimation by FCI and actual lesion size according to NHS histopathology results.
Baseline
Secondary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Comparison of DCIS lesion measurements using FCI and 3T MRI.
Extent of agreement in lesion size measurements between FCI and conventional 3T MRI.
Baseline
Participation Assistant
Eligibility Criteria

Eligible Ages
Adult, Older Adult
Minimum Age
18 Years
Eligible Sexes
Female
  • Females ≥ 18 years old.
  • Subjects diagnosed with DCIS on initial biopsy.
  • Lesion size >1 cm on imaging.
  • Subjects undergoing surgery as part of their treatment.
  • Able to fit comfortably in the scanners.
  • Able to understand written and spoken English.

  • Subjects undergoing chemotherapy or hormonal therapy.
  • Individuals unable to give informed consent.
  • Contra-indications to MRI scanning such as implantable cardiac devices.
  • Known allergy to contrast agent.
University of Aberdeen logoUniversity of Aberdeen
NHS Grampian logoNHS Grampian
Study Central Contact
Contact: Vasiliki Mallikourti, PhD, +44 1224 437831, [email protected]
1 Study Locations in 1 Countries
University of Aberdeen, Aberdeen, United Kingdom
Vasiliki Mallikourti, PhD, Contact, +44 1224 437831, [email protected]
Gerald Lip, Dr, Contact, [email protected]